Irritable bowel syndrome (IBS) is a group of symptoms related to functional gastrointestinal disorder characterized by uncomfortable abdominal pain and changes in the bowel movements. IBS classified into four main types based on the type of bowel movement which includes diarrhoea, constipation, in curtain conditions both are common or neither occurs very often (IBS-D, IBS-C, IBS-M/IBS-A, or IBS-U, respectively). IBS previously referred as spastic or nervous colon and spastic bowel.

The exact cause of IBS is not known. The cause many be due to combinations of gut-brain axis problems, gut motility disorders, pain sensitivity, infections including small intestinal bacterial overgrowth, neurotransmitters, genetic factors and food sensitivity.

The symptoms of IBS are abdominal pain or discomfort along with cramping or bloating with frequent diarrhoea or constipation and also change in bowel habits. The other symptoms of IBS incudes gastroesophageal reflux relating to genitourinary system, fibromyalgia, headache, backache and along with psychiatric symptoms such as depression and anxiety. One third of adults reporting sexual dysfunction, typically in the form of a reduction in libido.

There is no specific laboratory testing or imaging for irritable bowel syndrome. The diagnosis is based on symptoms, performance of specific investigations to rule out organic diseases which present similar symptoms. Basic investigations performed including stool microscopy and culture, blood tests, abdominal ultrasound, endoscopy, biopsies and hydrogen breath testing.

There are number of treatments which are found to be effective including psychotherapy, fiber therapy, antispasmodic and also antidepressant medication, peppermint oil, respectively.

Report Highlights

Global Insight Service’s, Irritable Bowel Syndrome – Drug Pipeline Landscape, 2022 report provides an overview of the Irritable Bowel Syndrome pipeline drugs. This report covers detailed insights on Irritable Bowel Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Irritable Bowel Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Table of Contents

List of Tables
List of Figures

1. Introduction
1.1 Irritable Bowel Syndrome – Pipeline Drugs, 2022-Coverage

2. Disease Overview – Irritable Bowel Syndrome
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management

3. Irritable Bowel Syndrome – Pipeline Drugs Development – Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2022
3.3 Products under Development by Companies, 2022

4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration

5. Drug Profiles
5.1 Clinical Stage Drugs – Phase III
5.1.1 Eluxadoline
5.2 Clinical Stage Drugs – Phase II
5.2.1 Aemcolo
5.2.2 Aldafermin
5.2.3 Blautix
5.2.4 ChiRhoStim
5.2.5 CIN-103
5.2.6 DS-01
5.2.7 ORP-101
5.2.8 Plecanatide
5.2.9 RHB-102
5.2.10 Rifamycin
5.2.11 SK08
5.3 Clinical Stage Drugs – Phase I
5.3.1 CSTI-300
5.3.2 DA-6886
5.3.3 EMD-RX5
5.3.4 IMU-856
5.3.5 Izencitinib
5.3.6 RQ-00310941
5.3.7 SVT-1B149
5.4 Early Stage Drugs – Preclinical
5.4.1 BLUE-181
5.4.2 BMC426
5.4.3 Bone Marrow MSC Derived Extracellular Vesicle Isolate
5.4.4 Drugs for IBS
5.4.5 IMC-1
5.4.6 IN-B012
5.4.7 MET642
5.4.8 NBTX-001
5.4.9 OCT461201
5.4.10 Ser224
5.5 Early Stage Drugs – Discovery
5.5.1 Drug for IBS
5.6 Clinical Stage Drugs – Unknown
5.6.1 Alpha-hel-CRF(9-41)
5.6.2 TNP-2092
5.6.3 VBX-100

6. Key Regulatory Designations

7. Key Deals

8. Key Upcoming Milestones

9. Key Companies Involved
9.1 4D Pharma Plc
9.2 AbbVie Inc
9.3 Bausch Health Americas, Inc.
9.4 Biomica
9.5 Blue Therapeutics Inc
9.6 CB2 Therapeutics Inc
9.7 ChiRhoClin, Inc
9.8 CinRx Pharma LLC
9.9 ConSynance Therapeutics Inc
9.10 Cosmo Pharmaceuticals NV
9.11 Direct Biologics, LLC
9.12 Dong-A ST Co Ltd
9.13 Emyria Ltd
9.14 HK inno.N Corp
9.15 Immunic Inc
9.16 Malachite Innovations, Inc
9.17 Metacrine Inc
9.18 NGM Biopharmaceuticals, Inc
9.19 Nobilis Therapeutics
9.20 Novome Biotechnologies Inc
9.21 Orphomed Inc
9.22 Oxford Cannabinoid Technologies Ltd
9.23 RaQualia Pharma Inc
9.24 RedHill Biopharma Ltd
9.25 Seed Health Inc
9.26 Sentia Medical Sciences
9.27 Serentrix LLC
9.28 Servatus Ltd
9.29 TenNor Therapeutics Ltd
9.30 Theravance Biopharma
9.31 Virios Therapeutics
9.32 Zhiyi Pharmaceuticals Inc

List of Tables

Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2.1 Clinical Trial Details – Aemcolo/Cosmo Pharmaceuticals NV
Table 2.2 Clinical Trial Details – Aldafermin/NGM Biopharmaceuticals, Inc
Table 2.3 Clinical Trial Details – Blautix/4D Pharma Plc
Table 2.4 Clinical Trial Details – CSTI-300/ConSynance Therapeutics Inc
Table 2.5 Clinical Trial Details – DA-6886/Dong-A ST Co Ltd
Table 2.6 Clinical Trial Details – DS-01/Seed Health Inc
Table 2.7 Clinical Trial Details – Eluxadoline/AbbVie Inc
Table 2.8 Clinical Trial Details – ORP-101/Orphomed Inc
Table 2.9 Clinical Trial Details – Plecanatide/Bausch Health Americas, Inc.
Table 2.10 Clinical Trial Details – RHB-102/RedHill Biopharma Ltd
Table 2.11 Clinical Trial Details – Rifamycin /RedHill Biopharma LtdTable
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
Table 4. 2 Discontinued Drugs

List of Figures

Figure 1. 1 Number of Products under Development for Irritable Bowel Syndrome, 2022
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Irritable Bowel Syndrome, 2022
Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Irritable Bowel Syndrome, 2022
Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Irritable Bowel Syndrome, 2022
Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Irritable Bowel Syndrome, 2022

Report Segmentation
  • Assessment by Stage of Development
  • Assessment by Companies
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Molecule Type
  • Assessment by Route of Administration

Order this Report

Have questions about the scope of the report ?

Have specific requirements ?

Budget Constraints ?

Related Reports

Diabetic neuropathy is a type of nerve damage…
Leukemia is a malignant disease of the blood…
Diabetic Gastroparesis is a serious complication of diabetes…